CLINICAL TRIALS PROFILE FOR METRELEPTIN

All Clinical Trials for metreleptin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00025883 ↗	Leptin to Treat Lipodystrophy	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2001-10-01	This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells. They also lack the hormone leptin, which is produced by fat cells. The leptin deficiency usually causes high blood lipid (fat) levels and insulin resistance that may lead to diabetes. Patients may have hormone imbalances, fertility problems, large appetite, and liver disease due to fat accumulation. Patients age greater than or equal to 6 months with significant lipodystrophy may be eligible for this study. Participants will be admitted to the NIH Clinical Center for 10 days for the following studies before beginning 12 months of leptin therapy: - Insulin tolerance test - Ultrasound of the liver and, if abnormalities are found, possibly liver biopsies. - Fasting blood tests - Resting metabolic rate - Magnetic resonance imaging of the liver and other organs, and of muscle and fat. - Pelvic ultrasound in women to detect ovarian cysts. - Estimation of body fat - Oral glucose tolerance test - Intravenous glucose tolerance test - Appetite level and food intake - Hormone function tests - Questionnaires to assess activity and mood - 24-hour urine collections Additional studies may include blood tests for genetic studies of lipodystrophy, a muscle biopsy to study muscle proteins involved in regulating energy expenditure before and after leptin replacement, and examination of a surgical specimen (if available) to study molecules that may be involved in energy storage and use. When the above tests are completed, leptin therapy begins. The drug is injected under the skin twice a day for 4 months and then once a day, if feasible. The dose is increased at the 1- and 2-month visits. Follow-up visits at 1, 2, 4, 6, 8 and 12 months after therapy starts include a physical examination, blood tests and a meeting with a dietitian. At the end of 12 months, all baseline studies described above are repeated. Patients record their symptoms weekly throughout the study. Those with diabetes measure their blood glucose levels daily before each meal and at bedtime.
NCT00085982 ↗	Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance	Recruiting	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-08-21	Study Description: Patients with mutations of the insulin receptor have diabetes that is challenging to control withconventional therapies, leading to early morbidity and mortality. We hypothesize that recombinant leptin (metrel eptin) in these patients will improve glycemia control. Objectives: Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in patients with genetic defects of the insulin receptor. Secondary Objectives: To determine mechanisms by which metreleptin improves glycemia. Endpoints: Primary Endpoint: Hemoglobin A1c. Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide, glucose/insulin/C-peptide area under the curve during oral glucose tolerance test. Study Population: 20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at the NIH Clinical Center. Description of Sites/Facilities Enrolling Participants: Description of Study Intervention: NIH Clinical Center Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).
NCT00130117 ↗	Study of Leptin for the Treatment of Hypothalamic Amenorrhea	Completed	Amgen	Phase 2	2010-04-01	The purpose of this study is to determine whether administration of an investigational medication called leptin (r-metHuLeptin) in replacement doses can improve bone health, reproductive function, hormone levels, immune function, and overall sense of well-being in women with hypothalamic (exercise-induced) amenorrhea (HA) who are being treated with oral contraceptive pills (OCPs), compared to placebo. Women with hypothalamic amenorrhea have low leptin levels. This study is based on the hypothesis that the relative leptin deficiency in women with hypothalamic (exercise-induced) amenorrhea may be the reason for the lack of menstrual cycles, hormone abnormalities, and bone loss associated with this condition.
NCT00130117 ↗	Study of Leptin for the Treatment of Hypothalamic Amenorrhea	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	2010-04-01	The purpose of this study is to determine whether administration of an investigational medication called leptin (r-metHuLeptin) in replacement doses can improve bone health, reproductive function, hormone levels, immune function, and overall sense of well-being in women with hypothalamic (exercise-induced) amenorrhea (HA) who are being treated with oral contraceptive pills (OCPs), compared to placebo. Women with hypothalamic amenorrhea have low leptin levels. This study is based on the hypothesis that the relative leptin deficiency in women with hypothalamic (exercise-induced) amenorrhea may be the reason for the lack of menstrual cycles, hormone abnormalities, and bone loss associated with this condition.

Clinical Trial Conditions for metreleptin

Condition Name

Condition Name for metreleptin
Intervention	Trials
Obesity	8
Lipodystrophy	6
Diabetes	4
Familial Partial Lipodystrophy	3

Condition MeSH

Condition MeSH for metreleptin
Intervention	Trials
Lipodystrophy	11
Lipodystrophy, Familial Partial	4
Lipodystrophy, Congenital Generalized	4
Body Weight	4

Clinical Trial Locations for metreleptin

Trials by Country

Trials by Country for metreleptin
Location	Trials
United States	112
Germany	2
France	2
Italy	2
Belgium	1

Trials by US State

Trials by US State for metreleptin
Location	Trials
Michigan	10
Texas	8
Florida	7
Massachusetts	7
Maryland	6

Clinical Trial Progress for metreleptin

Clinical Trial Phase

Clinical Trial Phase for metreleptin
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	3
PHASE2	1

Clinical Trial Status

Clinical Trial Status for metreleptin
Clinical Trial Phase	Trials
Completed	16
Recruiting	6
Terminated	3

Clinical Trial Sponsors for metreleptin

Sponsor Name

Sponsor Name for metreleptin
Sponsor	Trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	13
University of Michigan	5
Amryt Pharma	5

Sponsor Type

Sponsor Type for metreleptin
Sponsor	Trials
Other	20
Industry	18
NIH	17

Metreleptin (Myalept) Clinical Trials Update and Market Outlook

Last updated: May 3, 2026

What is metreleptin and how is it positioned commercially?

Metreleptin is a recombinant analog of human leptin used to treat leptin deficiency states. In market practice it is approved in multiple geographies under brand Myalept (and related brandings depending on jurisdiction). It also carries significant risk controls and product access restrictions in several markets due to safety findings and the resulting restricted-use frameworks.

From a market-access standpoint, metreleptin is not a broad-market endocrine drug category play. It is a niche, high-cost, low-prevalence therapy with prescriber and payer controls that often limit diffusion to diagnosed leptin deficiency populations.

What is the current clinical-trials landscape for metreleptin?

A complete global “as-of-today” clinical-trials map requires up-to-date registry pulls. That level of registry coverage cannot be produced with the information available in this session, so a full trial-by-trial update with endpoints, status, recruitment totals, and timelines cannot be issued here.

What can be stated from established commercial and regulatory reality is that metreleptin’s clinical program and label evolution have been heavily shaped by safety monitoring requirements and restricted-use policies, which in turn constrain trial recruitment and expansion beyond the leptin deficiency populations.

How does the restricted-use framework affect development and adoption?

Across markets where metreleptin is approved, restricted access is a defining constraint. This drives:

• Trial design focus on patients with confirmed leptin deficiency and carefully monitored safety endpoints
• Slower real-world uptake relative to typical orphan-drug diffusion
• Payer and site-level barriers (specialty prescribing, prior authorization, and documentation requirements)
• Higher operational burden for centers managing metabolic complications and long-term monitoring

For business planning, the key implication is that incremental clinical progress that does not directly expand label-eligible cohorts or improve access pathways will have limited top-line impact.

What market segments drive demand for metreleptin?

Demand clusters into two practical buckets:

1. Confirmed leptin deficiency phenotypes

• Pediatric and adult subgroups where leptin deficiency is clinically and/or diagnostically established.
• Sales are driven by diagnosis rates, referral pathways to specialized metabolic centers, and adherence to restricted-use criteria.

2. Substitutes within the metabolic rare-disease workflow

• In many settings, unmet need exists for metabolic complications and body composition dysregulation associated with leptin deficiency states, but product uptake still depends on eligibility criteria and safety requirements.
• Competing management strategies (dietary regimens, supportive care, other endocrine/metabolic approaches) can reduce net incremental demand even within the eligible population.

What do pricing and payer controls imply for revenue scale?

Metreleptin pricing is structurally constrained by orphan status and restricted-use protocols. Even with stable uptake, revenue growth tends to come from:

• Diagnosis expansion and earlier detection
• Improved center familiarity and streamlined eligibility documentation
• Contracting/payer policy stabilization that lowers administrative friction
• Label-adjacent evidence that supports continued use under controlled frameworks

Revenue acceleration that relies on broadening use beyond leptin deficiency tends to be difficult because restricted-use frameworks and safety constraints are hard to loosen without robust evidence.

Market projection framework (scenario logic built for constrained orphan access)

A defensible projection for a restricted-use orphan protein therapy is built on four drivers:

1. Eligible patient pool (diagnosis rate and eligibility criteria adherence)
2. Treatment penetration (share of eligible patients actually initiated and maintained)
3. Duration-of-therapy retention (discontinuation rates and safety event impact)
4. Net price realization (payer mix, rebates, and access friction)

Given the absence of registry-level trial updates and the absence of jurisdiction-specific pricing and reimbursement data in this session, only a structural projection model can be stated, not a quantified revenue forecast.

That structural model implies:

• Base-case growth is most sensitive to penetration and retention rather than pure patient incidence.
• Upside requires either evidence that supports broader eligibility within existing restricted-use terms or improved real-world access policies.
• Downside risk concentrates in safety-related restrictions that further narrow initiation or increase discontinuation.

Competitive and therapeutic substitution dynamics

Metreleptin competes indirectly with:

• Supportive metabolic management
• Other endocrine/metabolic interventions used for overlapping clinical features
• Emerging therapies targeting rare metabolic pathways (where access and eligibility may differ)

Because metreleptin’s differentiation is tied to leptin replacement in leptin deficiency states, substitution pressure is highest when:

• Diagnostic certainty is lower
• Patients are managed under broader syndromic categories rather than confirmed deficiency phenotypes
• Centers use alternative pathways due to administrative overhead or risk mitigation burdens

Key operational implications for R&D and investment decisions

What product signals matter most now?

With restricted-use reality, the most market-relevant evidence categories are:

• Safety durability in real-world and longer follow-up cohorts
• Evidence supporting continued use and reduced discontinuation under monitoring protocols
• Evidence improving eligibility clarity (diagnostic criteria, biomarkers, phenotyping rigor)
• Operational improvements that reduce time-to-treatment initiation

What trial outcomes are unlikely to move the market?

Outcomes with limited market relevance:

• Efficacy endpoints in populations that are not aligned with label-eligible leptin deficiency phenotypes
• Small, non-defining studies that do not translate into eligibility or access expansion
• Endpoints that do not align with payer-relevant safety and monitoring requirements

Regulatory and safety considerations that shape commercialization

Metreleptin’s restricted-use framework is the commercialization center of gravity. It typically governs:

• Patient selection documentation
• Monitoring schedules
• Risk communication to prescribers
• Ongoing pharmacovigilance and labeling constraints

In practice, these constraints control physician comfort, payer approval velocity, and discontinuation rates. Any clinical program that increases eligible volume must still clear safety-driven eligibility boundaries.

What is the actionable market outlook?

Base case

• Demand remains centered on known leptin deficiency populations.
• Growth is modest and driven primarily by diagnostic penetration and improved access mechanics.
• Net sales are sensitive to any further tightening of restricted-use criteria or safety-related discontinuation signals.

Upside case

• Meaningful growth occurs only if evidence supports expanded eligibility within the restricted-use structure or improves practical access (faster approvals, clearer diagnostic pathways).
• Uptake increases in centers with mature metabolic programs that can comply with monitoring.

Downside case

• A safety event pattern or regulatory tightening that further narrows initiation will compress penetration and increase discontinuation.
• Administrative friction rises when documentation or monitoring requirements expand.

Key Takeaways

• Metreleptin is a restricted-use orphan therapy whose commercial adoption depends more on eligibility and safety controls than on broad efficacy diffusion.
• A quantified clinical-trials update cannot be produced in this session without current registry-level status data.
• Market growth is most sensitive to eligible-pool definition, penetration, retention, and net price realization under payer and prescriber restrictions.
• Evidence that reduces discontinuation risk and clarifies eligibility has the highest probability of moving revenue trajectories.

FAQs

1. What patient group drives metreleptin demand most reliably?
   Confirmed leptin deficiency populations that meet restrictive label and risk-control criteria.

2. Why does metreleptin uptake tend to be slower than many orphan therapies?
   Restricted-use frameworks increase administrative burden, monitoring requirements, and initiation caution.

3. What clinical outcomes matter for commercialization?
   Safety durability, monitoring feasibility, and evidence that supports continued treatment under restricted-use rules.

4. What are the biggest revenue levers under restricted access?
   Treatment penetration among eligible patients, retention, and net price realization by payer mix.

5. Can trial efficacy alone drive large market expansion?
   Not without label-consistent eligibility expansion or practical access improvements that payers and prescribers will accept within risk controls.

References

[1] U.S. Food and Drug Administration. Myalept (metreleptin) prescribing information and safety-related communications. FDA label and safety updates.
[2] European Medicines Agency. Myalept (metreleptin) product information, EPAR, and restricted-use/safety guidance. EMA.
[3] ClinicalTrials.gov. Metreleptin (search results, study status and endpoints). U.S. National Library of Medicine.